N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.33
    -0.06 (-4.32%)

    Market Cap: $249.90M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(6/12)
    Avg Surprise
    -13.37%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.21 - $-0.17
    9 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.23-21.6%
    60d ago$-0.21-7.9%
    30d ago$-0.20-6.2%
    7d ago$-0.21-6.8%
    Current$-0.19
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.19 - $0.09
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 5
    		$-0.23$-0.23+0.00%Beat+30.3%
    Mar 26
    Reported May 7
    		$-0.30$-0.31+3.23%Beat+28.6%
    Dec 25
    Reported Mar 16
    		$-0.35$-0.47+25.53%Beat+5.4%
    Sep 25
    Reported Nov 6
    		$-0.35$-0.34-2.94%Miss+22.2%
    Jun 25
    Reported Aug 6
    		$-0.33$-0.37+10.81%Beat+10.8%
    Mar 25
    Reported May 12
    		$-0.42$-0.46+8.70%Beat-23.5%
    Dec 24
    Reported Mar 3
    		$-0.37$-0.44+15.91%Beat+47.9%
    Sep 24
    Reported Nov 12
    		$-0.45$-0.38-18.42%Miss+60.5%
    Jun 24
    Reported Aug 6
    		$-0.37$-0.36-2.78%Miss-33.0%
    Mar 24
    Reported May 7
    		$-0.34$-0.32-6.25%Miss-
    Dec 23
    Reported Mar 7
    		$-0.71$-0.55-29.09%Miss-
    Sep 23
    Reported Nov 1
    		$-1.14$-0.43-165.12%Miss-
    Jun 23
    Reported Aug 30
    		$-0.28$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.08EV/EBITDA-4.65x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-187.10%ROIC-217.02%
    Financial Health
    Debt/Equity1.19xInterest Coverage-39.22x
    Current Ratio4.50xQuick Ratio4.50x
    Trading Statistics
    Beta2.78Avg Volume708.57K
    52-Week High$3.6552-Week Low$0.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.52
    SMA 20$1.58
    SMA 50$1.60
    SMA 200$2.09
    EMA 10$1.49
    EMA 20$1.55
    EMA 50$1.62
    EMA 200$1.87

    MACD

    Line: -0.05Signal: -0.03Hist: -0.03

    ADX

    ADX: 13.5+DI: 14.5-DI: 29.9

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down100.0
    PSAR$1.72

    Bollinger Bands

    Upper Band$1.78
    Lower Band$1.37
    %B Position2594%(Upper)
    Band Width-0.11

    RSI (14-Day)

    Neutral
    36.1

    Momentum Oscillators

    Stoch %K3.6
    Stoch %D11.0
    Williams %R-97.8
    ROC (10d)-12.5%
    Momentum-0.19
    CCI (20d)-209.1
    MFI (14d)32.4

    Volatility Measures

    ATR (14d)$0.12(8.9%)
    StdDev (20d)0.10
    Hist Vol74.7%(High)

    Volume Flow

    VWAP$1.36
    OBV67.0M
    AD Line18.3M
    CMF (20d)-0.239

    Volume Metrics

    Avg Vol (20d)724.4K
    Vol Ratio0.9x
    VWMA (20d)$1.57

    Pivot Points

    R3$1.60
    R2$1.56
    R1$1.47
    Pivot Point$1.43
    S1$1.34
    S2$1.30
    S3$1.21

    Advanced Oscillators

    TSI-12.70
    Ultimate Osc37.1
    KST-56.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0$318,000$0$0$0$166,000$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$-166,000$0
    Operating Expenses$42.19M$52.86M$58.48M$57.70M$54.04M$70.94M$62.92M$76.65M$63.82M$60.07M$114.00M$56.86M
    R&D$29.28M$38.60M$44.67M$45.52M$38.72M$52.15M$45.91M$60.63M$48.63M$45.76M$102.77M$41.60M
    SG&A$12.91M$14.27M$13.81M$12.18M$15.32M$18.79M$17.01M$16.02M$15.19M$14.32M$11.24M$15.26M
    Operating Income$-42,190,000$-52,864,000$-58,480,000$-57,700,000$-54,040,000$-70,936,000$-62,922,000$-76,646,000$-63,822,000$-60,074,000$-114,004,000$-56,864,000
    Interest Income$935,000$1.23M$1.77M$1.69M$2.25M$3.07M$4.09M$4.21M$5.27M$6.37M$5.65M$3.84M
    Interest Expense$1.82M$1.85M$970,000$747,000$436,000$0$0$0$0$0$30.08M$0
    Income Before Tax$-43,082,000$-53,428,000$-59,450,000$-56,755,000$-52,706,000$-67,887,000$-58,819,000$-72,494,000$-58,575,000$-53,721,000$-144,087,000$-53,027,000
    Income Tax Expense$0$30,000$0$0$25,000$105,000$0$53,000$125,000$0$268,000$0
    Net Income$-43,082,000$-53,458,000$-59,450,000$-56,755,000$-52,731,000$-67,992,000$-58,819,000$-72,547,000$-58,700,000$-53,721,000$-108,730,000$-53,027,000
    EBITDA$-41,796,000$-52,379,000$-59,256,000$-54,969,000$-54,198,000$-70,804,000$-62,750,000$-76,547,000$-63,686,000$-59,928,000$-113,942,000$-56,692,000
    EBIT$-42,197,000$-52,805,000$-58,749,000$-57,693,000$-54,520,000$-70,961,000$-62,907,000$-76,703,000$-63,846,000$-60,086,000$-114,108,000$-56,865,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NMRA

    News

    Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts

    Neumora Therapeutics (NASDAQ:NMRA) has received an average "Moderate Buy" rating from analysts, with a consensus price target of $6.57, despite recent reductions by some firms. The company's shares opened at $1.52, trading below key moving averages, and it recently slightly beat EPS expectations. Insider selling has occurred, but hedge funds and institutional investors hold a significant portion of the stock.

    MarketBeat•8/25/26•
    Somewhat-Bearish

    2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC

    ICONIQ Capital LLC has purchased 2,559,090 shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA), amounting to a 1.38% stake valued at approximately $4.35 million. Other institutional investors have also increased their holdings, bringing total institutional ownership to 47.65%. Despite a "Moderate Buy" consensus rating and a $6.57 average price target from analysts, the stock has seen mixed analyst actions and insider selling.

    MarketBeat•8/24/26•
    Neutral

    Neumora Therapeutics COO Aurora disposes of $269,966 in stock

    Daljit Singh Aurora, COO of Neumora Therapeutics (NASDAQ:NMRA), disposed of 176,060 shares of company stock worth approximately $269,966 across August 20 and 21, 2026. These sales followed option exercises at a lower price. The transactions occurred while NMRA stock trades significantly below its 52-week high, and amidst recent news of the company discontinuing a major drug development program and reducing its workforce.

    Investing.com•8/22/26•
    Neutral

    Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Joshua

    This document is a statement of changes in beneficial ownership of securities for Neumora Therapeutics, specifically pertaining to Officer Pinto Joshua. It is a mandatory filing, typically submitted to regulatory bodies like the SEC, to report transactions by company insiders. The document details modifications in the officer's holdings of company stock or other securities.

    Moomoo•8/22/26•
    Neutral

    Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

    Daljit Singh Aurora, an insider at Neumora Therapeutics (NASDAQ:NMRA), sold 21,055 shares of the company's stock for approximately $33,688 on August 21st, 2026, reducing his position by over 30%. This sale is part of multiple transactions he made between August 17th and August 21st. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating with an average price target of $6.57, though some recent price targets have been lowered.

    MarketBeat•8/22/26•
    Somewhat-Bearish

    Frequently Asked Questions About NMRA

    Does NMRA pay dividends?
    Neumora Therapeutics, Inc. (NMRA) does not currently pay a regular dividend.
    What is NMRA's market cap?
    Neumora Therapeutics, Inc. (NMRA) has a market capitalization of $249.90M with a current stock price of $1.33.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In